CD274 Recombinant Antibody: Enhance Your Research with Quality Solutions

Alpha Lifetech Incorporation presents its advanced cd274 recombinant antibody, a pivotal tool in immunological research and therapeutic development. CD274, also known as PD-L1, plays a critical role in the immune response by regulating T-cell activation. This high-quality recombinant antibody is designed for optimal specificity and sensitivity, making it an essential asset for studies in cancer biology and immunotherapy, Our CD274 antibody is produced using state-of-the-art techniques to ensure uniformity and reliability, allowing researchers to achieve consistent results in their experiments. With applications in ELISA, Western blotting, and immunohistochemistry, this antibody facilitates the exploration of the PD-1/PD-L1 pathway and its implications in tumor microenvironments, Choose Alpha Lifetech's CD274 recombinant antibody to enhance your research in cancer immunology and unlock new possibilities in therapeutic strategies. Experience unparalleled quality and support as you advance your studies and contribute to innovative treatments

Hot Selling Product

ADT1382-Manelimab Biosimilar-Anti-CD274/PD-L1/B7-H1 mAb-Research Grade

ALP64625-Recombinant Human CD274/PD-L1/B7-H1 Protein, Flag Tag

ALP64632-Recombinant Human CD274/PD-L1/B7-H1 Protein, His Tag

ALP64655-Recombinant Cynomolgus Monkey CD274/PD-L1/B7-H1 Protein, His Tag

ADT1472-Opucolimab Biosimilar-(B7-H1/PD-L1/CD274)-Research Biosimilar Antibody

ADT1608-Sugemalimab Biosimilar-(B7-H1/PD-L1/CD274)-Research Biosimilar Antibody

How To Select CD274 recombinant antibody Industry Giant Manufacturers You Can Rely On

Selecting a reliable manufacturer for CD274 recombinant antibodies is crucial for researchers and companies aiming to develop effective therapeutics. With the increasing demand for high-quality reagents, it becomes essential to partner with industry giants that have proven expertise. One such leader in the field is Alpha Lifetech Inc., which boasts an impressive foundation built by a team of scientists with vast experience in membrane protein production, nanobody discovery, and monoclonal development. This strong scientific background ensures that their products, including nearly 10,000 unique membrane protein reagents and cytokines, meet the highest standards of quality and efficacy. When evaluating potential manufacturers, consider their track record in research and development. Alpha Lifetech Inc. not only offers a wide range of drug target antibodies but also emphasizes innovation by continuously expanding their product line. Furthermore, their commitment to quality control and customer service positions them as a reliable partner in the competitive landscape of biopharmaceutical research. By choosing a manufacturer like Alpha Lifetech Inc., global buyers can ensure they have access to cutting-edge research tools that can significantly advance their projects and drive discoveries in immunology and targeted therapies.

How To Select CD274 recombinant antibody Industry Giant Manufacturers You Can Rely On

Manufacturer	Quality Certifications	Product Range	Average Lead Time (Days)	Customer Satisfaction Rating
Manufacturer A	ISO 9001, ISO 13485	Monoclonal Antibodies, Recombinant Proteins	14	95%
Manufacturer B	GMP, ISO 9001	Recombinant Antibodies, ELISA Kits	30	90%
Manufacturer C	ISO 9001, CE	Antibody Conjugates, Research Reagents	20	88%
Manufacturer D	ISO 13485, GMP	Monoclonal & Polyclonal Antibodies	25	92%
Manufacturer E	ISO 9001, FDA Registered	Recombinant Antibodies, Cell Culture Products	18	93%

Annual Growth Trend of CD274 Recombinant Antibodies in the Biotechnology Industry

The biotechnology industry has seen significant growth in the market for CD274 recombinant antibodies over the past few years. Represented in the line chart above, sales figures illustrate a robust increase from $10 million in 2018 to an impressive $90 million in 2023. This upward trend reflects not only rising demand for these antibodies in therapeutic applications but also advancements in recombinant technology that facilitate their production. The increased investment in research and development, combined with expanding clinical applications in immunotherapy, has further propelled the growth of this market segment. Prospective buyers are encouraged to monitor these trends closely, as they may influence purchasing decisions when selecting reliable manufacturers for CD274 recombinant antibodies. This data highlights the industry's dynamic nature and the importance of partnering with manufacturers that align with these growth trends in product development and availability.